


NOW AVAILABLE FOR MILD TO MODERATE PLAQUE PSORIASIS



NEW Vectical™ – the only Vitamin D₃ ointment

- Naturally occurring, active form of Vitamin D₃
- May be used with other psoriasis agents¹
- Proven safe and effective in a 52-week safety study (N=324)¹
- Effective in as early as 2 weeks; at 8 weeks, 34% vs 22% with vehicle were clear or minimal²
- Convenient BID application³
- **No generic equivalent**



Available in 100-g tubes³:

Strength	Tube size	NDC #	Cardinal Health #	Amerisource #	McKesson #
3 mcg/g	100 g	02992012-10	4154605	679-159	3271400

The most frequent adverse events ($\geq 3\%$) reported in clinical trials were lab test abnormality, urine abnormality, psoriasis, hypercalciuria, pruritus and skin discomfort. Vectical™ should be used with caution in patients with known or suspected disturbances in calcium homeostasis, who are taking calcium or Vitamin D supplements or who are on diuretics. If aberrations in parameters of calcium metabolism occur, discontinue use until these normalize. Caution patients to avoid excessive exposure to natural or artificial sunlight after applying the ointment. Avoid contact with eyes, lips and face. Limit use to 200 grams per week.



© 2009 Galderma Laboratories, L.P.
 GALDERMA is a registered trademark.
 Galderma Laboratories, L.P., 14501 N. Freeway, Fort Worth, TX 76177
 VEC-324 Printed in USA 02/09

References: 1. Data on file. Galderma Laboratories. 2. Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 µg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. *J Drugs Dermatol.* 2007;6:428-435. 3. Vectical™ Prescribing Information. Fort Worth, TX: Galderma Laboratories, L.P.; 2009.

www.Vectical.com

Please click here for full Prescribing Information.

